Grampian BioPartners
Liberty Building Foresterhill Health Research Complex Foresterhill Road, Aberdeen, Aberdeenshire, AB25 2ZP, United Kingdom
Overview
GBP was founded in March 2008 by Professor Andy Porter and Drs Keith Charlton and Gillian Broadbent. GBP is an angel investment group that specialises in seed funding early stage life-science companies. Typical investments are of the order of £50-200k. This grouping is unusual because its internationally recognised scientific team is used by other agencies and investment groups to carry out scientific due diligence prior to their investment.GBP became a Scottish co-investment partner on 1st April 2010. To date the company has made ten investments in Scotland and one in a Malaysian company looking to relocate part of its business to Scotland.The company's major commercial and science focus covers immuno-diagnostics and devices, immuno-technology, biologic drug discovery. GBP has particular expertise in the areas of antibody diagnostics and biologic therapeutics. More recently it has also made early stage assessments and investments in regenerative medicine and vaccine/drug delivery companies.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Asset Management
- Impact Investing
Investment portfolio
- ImmunoSolv
Participated · Equity · Sep 2010
ImmunoSolv merged with Aberdeen-based Grampian BioConsultants to form ImmunoSolv Limited, combining complementary immunology and immuno-technology expertise. Its core product suite centers on the Dead-Cert® dead-cell removal reagents and a magnetic Dead-Cert® Nanoparticles device that separates viable cells from dead cells and debris in vitro. The merger aims to accelerate commercial sales of Dead-Cert® kits alongside GBC’s contract research services and to build technologies combining apoptosis detection/control with antibody engineering. Target applications include regenerative medicine, tailored protein therapeutics, diagnostic proteins, and progression of its anti-cancer and anti-inflammation biologics. The company has secured funding and grants that, together with University of Edinburgh investment, bring over £500K into the business. Management and the board were retained and expanded to support commercialization and R&D translation into clinical-grade products.
Team
No current team members are available.